3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
71
Terminated
25
Unknown
7
Withdrawn
5
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Leukemia, Myeloid, Acute
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms
5
Myelodysplastic Syndromes
4
Lymphoma, Non-Hodgkin
4
Hodgkin Disease
4
Rhabdomyosarcoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma
2
Leukemia, Myelomonocytic, Juvenile
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Biphenotypic, Acute
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Sarcoma, Myeloid
1
Sarcoma
1
Retinoblastoma
1
Neutropenia
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Multi-centric Castleman's Disease
1
Medulloblastoma
1
Malignant mesenchymal tumor
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, AIDS-Related
1
Lymphadenopathy
1
Interventions
Dexamethasone
117
Lenalidomide
77
daratumumab
59
Bortezomib
54
carfilzomib
41
Calcium Dobesilate
36
pomalidomide
35
Cyclophosphamide
27
isatuximab
23
belantamab mafodotin
22
Specimen Handling
20
Biopsy
20
Magnetic Resonance Spectroscopy
17
dexamethasone acetate
13
dexamethasone 21-phosphate
13
auricularum
12
Melphalan
12
selinexor
11
ixazomib
11
iberdomide
11
fludarabine
11
elotuzumab
11
fludarabine phosphate
8
talquetamab
7
X-Rays
7
trametinib
6
nirogacestat
6
venetoclax
5
Thalidomide
5
Nuclear Medicine Department, Hospital
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Multiple Myeloma
×
Filgrastim
×
Clear all
NCT03188172
2024-05-14
MUKnineb
University of Leeds
Phase 2
Active not recruiting
95 enrolled